Resumen Introducción: Los estigmas sociales en personas que viven con VIH han sido parte de su historia y aún se puede identificar en los entornos actuales de atención. Objetivo: Analizar los estigmas sociales en relación con la atención de las personas que viven con VIH por parte de quienes otorgan el servicio de vacunación anti Sars-CoV-2. Materiales y métodos: Se desarrolló una investigación cuantitativa descriptiva que incluyó una muestra censal de 126 personas. Se aplicó la Escala de estigma social en la atención de personas con VIH/SIDA. La información fue analizada a través del SPSS versión 25. Resultados: La mayoría de participantes refirió no conocer a personas con VIH, pero sí les han atendido como usuarios (54%), y consideró que son discriminadas (88,1%). Pese a que se evidenció un nivel bajo de estimas (71,4%), éstos están presentes en el 85,7%. El haber tenido contacto como usuario con personas con VIH se asoció con el nivel de estigma (p=0.008). Conclusiones: Se requiere fomentar capacitaciones en las que se aborde la complejidad del fenómeno y se identifiquen aspectos como los estigmas sociales, incorporando el paradigma biopsicosocial y con perspectiva de género en pro de la prestación integral de los cuidados.

Abstract Introduction: Social stigmas in people living with Human Immunodeficiency Virus (HIV) have been part of their history and can still be identified in today's care environments. Objective: To analyze the social stigmas in relation to the care of people living with HIV by those who provide the anti Sars-CoV-2 vaccination service. Materials and methods: A descriptive quantitative research were developed that included a census sample of 126 people. The scale of social stigma in the care of people with HIV/AIDS (Acquired immunodeficiency syndrome) was applied. The information was analyzed through SPSS version 25. Results: Most of the participants reported not knowing people with HIV, but they have been treated as users (54%) and considered that they are discriminated (88.1%). Although a low level of stigma was evidenced (71.4%), these are present in 85.7%. Having had contact as a user with people with HIV was associated with the level of stigma (p=0.008). Conclusions: It is necessary to promote training in which the complexity of the phenomenon is addressed and aspects such as social stigmas are identified, incorporating the biopsychosocial paradigm together with a gender perspective in favor of the comprehensive provision of care.

FUNDAMENTOS: A prevalência de candidíase oral em pacientes diabéticos é de 13,7- 64%. A espécie mais frequentemente isolada é Candida albicans(75-86,5%). OBJETIVO: Obter a prevalência de portadores de Candida em pacientes com diabetes mellitus tipo 2 para identificar as espécies da levedura. Desenho do estudo: Aberto, observacional, descritivo, transversal e prospectivo. MÉTODOS: Incluímos pacientes voluntários dentro da Maratona Nacional do Diabetes e realizamos medida da glicose sanguínea, teste sialométrico, coloração de Gram da citologia esfoliativa, cultura em ágar Sabouraud dextrose e CHROMagar Candida TM. Os resultados foram analisados com estatística descritiva. RESULTADOS: Foram examinados 141 pacientes (média de idade de 57 anos), 103 mulheres (73%) e 38 homens (26,9%). A citologia esfoliativa foi positiva em 32 casos (23 com lesão oral), 78 tinham lesão oral, mas não tinham Candida (93,9%). Candida foi isolado em 58 pacientes (41,1%), 21(45,6%) tiveram glicemia superior a 126 mg / dl e 37 (38,9%) tiveram glicemia inferior a 126 mg / dl. A espécie mais frequente foi C. albicans (82,7%). 42 portadores de Candida tinham fluxo salivar maior que 20 mm(72,4%) e 16(27,5%) tinham hiposalivação. Candida foi isolado em 25 de 79 pacientes com prótese dentária (31,6%), 9 de 15 fumantes (60%), e 22 de 71 com sintomas (30,9%). CONCLUSÕES: A prevalência de portadores de Candida oral em pacientes com diabetes mellitus tipo 2 no México foi semelhante a outros países; citologia esfoliativa foi efetiva em encontrar Candida; fluxo salivar, uso de prótese, presença de lesão oral e sintomatologia foi semelhante em portadores de Candida oral e pacientes não portadores. A maioria dos fumantes eram portadores de Candida.

BACKGROUND: Prevalence of oral candidiasis in diabetic patients is 13.7-64%. Candida albicans was the most frequently isolated species (75-86.5%). OBJECTIVE: To obtain the prevalence of Candida carriers among patients with type 2 diabetes mellitus to identify the species of the yeast. Study design: It is an open, observational, descriptive, cross-sectional, and prospective study. METHODS: We included voluntary patients from the National Diabetes Marathon and performed a blood glucose measurement, sialometry test, Gram-stained exfoliative cytology, and culture on Sabouraud dextrose agar and CHROMagar Candida TM. Results were analyzed using descriptive statistics. RESULTS: We examined 141 patients (mean age 57 years): 103 women (73%) and 38 men (26.9%). Exfoliative cytology was positive in 32 cases (23 with oral lesions); 78 had oral lesions but no Candida (93.9%). Candida was isolated in 58 patients (41.1%), 21 (45.6 %) had blood glucose greater than 126 mg/dl, and 37 (38.9%) had less than 126 mg/dl. The most frequent species was C. albicans (82.7%). Forty-two Candida carriers had salivary flow greater than 20 mm (72.4%), and 16 (27.5%) had hyposalivation. Candida was isolated in 25 of 79 patients with dental prosthesis (31.6%), 9 of 15 were smokers (60%), and 22 of 71 had symptoms (30.9%). CONCLUSIONS: Prevalence of oral Candida carriers in patients with type 2 diabetes mellitus in Mexico was similar to that found in other countries; exfoliative cytology was effective in finding Candida; salivary flow rate, use of prosthesis, and presence of oral lesions and symptoms were similar in oral Candida carriers and negative patients. Most smokers were Candida carriers.